--- title: "Allient (ALNT) Rejoins Russell Focus As Investors Ask If The Stock Is Already Priced In" type: "News" locale: "en" url: "https://longbridge.com/en/news/291471995.md" description: "Allient (ALNT) rejoins the Russell 2000 Defensive indexes, triggering potential mechanical trading. Despite recent strong momentum and a current price of $98.63, analysts consider the stock overvalued, with a consensus fair value target of $69.10. While some bullish targets reach $79.0, bearish views sit at $52.5. Investors are debating whether future growth is already priced in, though margin improvements in aerospace and defense could surprise expectations." datetime: "2026-07-01T23:52:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291471995.md) - [en](https://longbridge.com/en/news/291471995.md) - [zh-HK](https://longbridge.com/zh-HK/news/291471995.md) --- # Allient (ALNT) Rejoins Russell Focus As Investors Ask If The Stock Is Already Priced In ## Index reshuffle puts Allient in focus Allient (ALNT) has been dropped from several Russell value and small cap benchmarks and added to the Russell 2000 Defensive and Russell 2000 Growth Defensive indexes, a shift that can prompt mechanical trading and portfolio rebalancing. See our latest analysis for Allient. Despite a 1-day share price decline of 4.18% to US$98.63 around the index reshuffle, Allient has seen strong momentum recently, with a 30-day share price return of 18.72% and a 1-year total shareholder return of 159.70%. If index changes have you thinking about where else capital is moving, this may be a good moment to broaden your search using the 35 power grid technology and infrastructure stocks. With Allient now trading at US$98.63 against an analyst price target of US$73.80 and an indicated intrinsic premium of about 51%, investors have to ask: is there still value here, or is the market already pricing in future growth? ## Most Popular Narrative: 43% Overvalued The most followed narrative currently pegs Allient's fair value at $69.10, well below the last close at $98.63. This sets up a clear valuation gap for investors to examine. > _The analysts have a consensus price target of $69.1 for Allient based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $79.0, and the most bearish reporting a price target of just $52.5._ _Read the complete narrative._ Want to see what is sitting underneath that fair value line? The narrative leans heavily on steady revenue growth, thicker margins, and a richer earnings multiple than many might expect. **Result: Fair Value of $69.10 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, Allient could still surprise this consensus if its push into higher value aerospace, defense and medical work improves margins faster than analysts currently model. Find out about the key risks to this Allient narrative. ## Next Steps The mix of optimism and caution around Allient is clear. If you want to move quickly and decide for yourself, start by weighing the 2 key rewards and 1 important warning sign. ## Looking for more ideas beyond Allient? If Allient has your attention, do not stop there. Broaden your watchlist with a few focused stock ideas surfaced by the Simply Wall St screener. - Target potential mispricings by scanning companies that combine quality fundamentals with attractive valuations using the 41 high quality undervalued stocks. - Strengthen your income stream by reviewing stocks that appear in the 8 dividend fortresses and offer sizeable yields with supporting fundamentals. - Prioritise capital protection by shortlisting companies highlighted in the 73 resilient stocks with low risk scores that show lower risk scores alongside more resilient profiles. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ALNT.US](https://longbridge.com/en/quote/ALNT.US.md) ## Related News & Research - [Allient CEO Richard Warzala disposes of common shares worth $9.09 million](https://longbridge.com/en/news/295712422.md) - [Batten down the hatches and allocate defensively because global liquidity has peaked, argues veteran strategist](https://longbridge.com/en/news/295919967.md) - [Milestone Scientific Q2 revenue rises 22% on medical segment growth, reaffirms 2026 outlook](https://longbridge.com/en/news/295928913.md) - [11:21 ETAdventHealth Wesley Chapel unveils advanced stroke intervention technology, bringing lifesaving thrombectomy care to Pasco County](https://longbridge.com/en/news/296248721.md) - [THCH: Revenue and same-store sales fell sharply in Q2 2026 amid competition and strategic store closures](https://longbridge.com/en/news/296238737.md)